The combination of bamlanivimab and etesevimab reduces the risk of COVID-19-related hospitalization and any-cause death in high-risk ambulatory patients, particularly those with diabetes, according to the BLAZE-1* study presented at EASD 2021.
The US Food and Drug Administration has given the green light to Moderna and Johnson & Johnson’s COVID-19 booster shots for eligible populations amid reports of waning immunity and breakthrough infections.
Though promising, coronavirus disease 2019 (COVID-19) symptom checkers—online, patient-led triage systems—are unable to reliably distinguish mild from severe COVID-19 and may instead put the public and healthcare workers at greater risk of infection, according to a recent study.
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.
Use of therapeutic heparin does not appear to significantly reduce the death, mechanical ventilation, or intensive care unit (ICU) admission in hospitalized patients with moderate COVID-19 and increased D-dimer levels, reveals a study. However, it is associated with a significantly lower chances of all-cause death and reduced risk of major bleeding.
In a systematic review and meta-analysis, glycaemic parameters in patients with type 1 diabetes (T1D) improved during the COVID-19 lockdown periods. Conversely, patients with type 2 diabetes (T2D) had short-term worsening of glycaemic values.
Reopening workplaces and establishments after the lifting of coronavirus disease 2019 (COVID-19) lockdowns leads to an increase in physical activity as well as notable shifts in sleep patterns and mental wellbeing, according to a recent Singapore study.
The investigational oral antiviral pill molnupiravir significantly slashed the risk of hospitalization or death by half in nonhospitalized adults with mild-to-moderate COVID-19, according to interim data from the phase III MOVe-OUT trial.